AVITA Medical Q1 Results Reflect Persistent Reimbursement Headwinds; Liquidity Concerns Loom

What happened

AVITA Medical's Q1 2026 financial results confirmed ongoing reimbursement pressures that have dampened demand for its RECELL system, with revenue likely declining as management had guided for a soft first half. The company reiterated expectations for a recovery in the second half of 2025, driven by advocacy progress and anticipated coverage beginning in Q4 2025. While management highlighted the adoption of RECELL GO and the recent Cohealyx clearance as growth catalysts, near-term execution remains challenged. Cash and cash equivalents fell to ~$12 million, and interest expenses continued to rise, intensifying liquidity risk. The results reinforce the balanced risk/reward profile, with no material change to the thesis, but the margin for error is narrowing.

Implication

The Q1 results align with our HOLD/NEUTRAL stance, confirming reimbursement headwinds and cash burn. Upside hinges on a credible 2H25 recovery, driven by RECELL GO adoption and payer coverage. Downside risks include prolonged weakness and potential dilutive financing. We maintain a cautious view until tangible improvement in per-center procedures and liquidity is evident.

Thesis delta

The Q1 2026 results validate the reimbursement-driven softness we anticipated, with no signs of near-term improvement. However, the accelerated cash burn raises the stakes for a second-half recovery, increasing downside risk if execution falters. No change to our HOLD/NEUTRAL recommendation, but the timeline for catalysts has become more critical.